

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number: WO 99/42486
C07K 14/78, C12P 21/02		(43) International Publication Date: 26 August 1999 (26.08.99)

(21) International Application Number:	PCT/US99/03271	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	19 February 1999 (19.02.99)	
(30) Priority Data:		
60/075,587	23 February 1998 (23.02.98)	US
(71) Applicant (for all designated States except US):	G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	
(72) Inventors; and		
(75) Inventors/Applicants (for US only):	HARDING, Elizabeth, I. [US/US]; 568A Fieldmount Drive, Kirkwood, MO 63122 (US). VIOLAND, Bernard, N. [US/US]; 1710 Woods Bend Lane, Glencoe, MO 63038 (US).	
(74) Agents:	BENNETT, Dennis, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	

(54) Title: METHOD OF PRODUCING MOUSE AND HUMAN ENDOSTATIN**(57) Abstract**

Methods for producing mouse and human endostatin are disclosed. Methods for refolding and purifying endostatin from inclusion bodies expressed in bacteria and nucleic acids encoding full-length and truncated forms of endostatin are also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

Method of producing mouse and human endostatin

Priority

The present application claims priority under Title 35, United States Code, § 119 of United States Provisional Application Serial No. 60/075,587 filed February 5, 1998.

Field of the invention

Methods for producing mouse and human endostatin are disclosed. Methods for refolding and purifying endostatin from inclusion bodies expressed in bacteria and nucleic acids encoding full-length and truncated forms of endostatin are also disclosed.

Background of the invention

Angiogenesis

Angiogenesis, the growth of new blood vessels, plays an important role in cancer growth and metastasis. In humans, the extent of vasculature in a tumor has been shown to correlate with the patient prognosis for a variety of cancers (Folkman, J., *Seminars in Medicine of the Beth Israel Hospital, Boston* **333**(26): 1757-1763, 1995; Gasparini, G., *European Journal of Cancer* **32A**(14): 2485-2493, 1996; Pluda, J. M., *Seminars in Oncology* **24**(2): 203-218, 1997; Norrby, K., *APMIS* **105**: 417-437, 1997). In normal adults, angiogenesis is limited to well controlled situations, such as wound healing and the female reproductive system (Battegay, E.J., *J Mol Med* **73**: 333-346, 1995; Dvorak, H.F., *New Engl J Med*, **315**: 1650-1659, 20 1986).

Animal studies suggest that tumors can exist in a dormant state, in which tumor growth is limited by a balance between high rates of proliferation and high rates of apoptosis (Holmgren, L. et al., *Nat. Med. (N. Y.)* **1**(2): 149-153, 1995; Hanahan, D. et al., *Cell* **86**(3): 353-364, 1996). The switch to an angiogenic phenotype allows tumor cells to escape from dormancy and to grow rapidly,

- 2 -

presumably as the result of a decrease in the apoptotic rate of the tumor cells (Bouck, *Cancer Cells*, **2**(6): 179-185, 1990; Dameron et al, *Cold Spring Harb Symp Quant Biol*, **59**: 483-489, 1994). The control of angiogenesis is thought to be a balance between factors which promote new vessel formation and anti-angiogenic factors with suppress the formation of a neovasculature (Bouck, N. et al., *Advances in Cancer Research* **69**: 135-173, 1996; O'Reilly et al., *Cell* **79**(2): 315-328, 1994).

A variety of pro-angiogenic factors have been characterized including basic and acid fibroblast growth factors (bFGF and aFGF) and vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) (Potgens, A. J. G. et al., *Biol. Chem. Hoppe-Seyler* **376**: 57-70, 1995; Ferrara, N., *European Journal of Cancer* **32A**(14): 2413-2442, 1996; Bikfalvi, A. et al., *Endocrine Reviews* **18**: 26-45, 1997). Several endogenous anti-angiogenic factors have also been characterized, including angiostatin (O'Reilly et al., *Cell* **79**(2): 315-328, 1994), endostatin (O'Reilly et al., *Cell* **88**(2): 277-285, 1997), interferon-alpha. (Ezekowitz et al, *N. Engl. J. Med.*, *May 28*, **326**(22) 1456-1463, 1992), thrombospondin (Good et al, *Proc Natl Acad Sci USA* **87**(17): 6624-6628, 1990; Tolsma et al., *J Cell Biol* **122**(2): 497-511, 1993), and platelet factor 4 (PF4) (Maione et al, *Science* **247**(4938): 77-79, 1990).

Many angiogenic inhibitors are in clinical development (See Shawver et al., *Drug Discovery Today* **2**(2): 50-63, 1997, and references therein). Polypeptides such as interferon alpha and platelet factor 4 are in clinical trials. Angiostatin, soluble Flt-1 receptor, and bactericidal/permeability increasing protein derivative 23 are in preclinical studies. Monoclonal antibodies such as humanized anti-a_vb₃ antibody (LM609), anti-VEGF, and anti-Flk-1 monoclonal antibody (DC101) are also in preclinical studies. Tecogalan (DS4152), a sulfated polysaccharide-peptidoglycan complex is in clinical trials, and bFGF carbohydrate inhibitor (GM1474) and glyceptor mimetic inhibitor of bFGF (GL14.2) are in preclinical studies. The antibiotic AGM1470 (TNP470), a fumagillin analog, and Suramin, a polyanionic compound are in clinical trials. Small molecule inhibitors such as urokinase receptor antagonists, inhibitors of phosphatidic acid, inhibitors of Flk-1, and inhibitors of VEGF-F11 binding are all in preclinical studies. Thalidomide, and its analogues, and matrix metalloproteinase inhibitors, such as Batimastat/Marimastat, are in clinical trials. Oligonucleotides, such as ribozymes that target VEGF receptors and VEGF anti-sense oligonucleotides, are also in preclinical trials.

- 3 -

Anti-angiogenic therapy may offer several advantages over conventional chemotherapy for the treatment of cancer. Anti-angiogenic agents have low toxicity in preclinical trials and development of drug resistance has not been observed (Folkman, J., *Seminars in Medicine of the Beth Israel Hospital, Boston* 5 **333**(26): 1757-1763, 1995). As angiogenesis is a complex process, made up of many steps including invasion, proliferation and migration of endothelial cells, it can be anticipated that combination therapies may be most effective. In fact, combinations of chemotherapy with anti-angiogenic therapy have already shown promising results in pre-clinical models (Teicher, B. A. et al., *Breast Cancer Research and Treatment* 10 **36**: 227-236, 1995; Teicher, B. A. et al., *European Journal of Cancer* **32A**(14): 2461-2466, 1996).

Endostatin

Endostatin is a 20 kDa protein derived from the C-terminal fragment of alpha 1 type collagen XVIII. Conditioned cell culture media from a hemangioendothelioma cell line (EOMA) was shown to contain a factor which inhibited endothelial cell proliferation *in vitro* (O'Reilly et al., *Cell* 15 **88**: 277-285, 1997). The factor responsible for this inhibition was named endostatin. A recombinant form of this protein expressed in baculovirus-infected insect cells inhibited the growth of metastases in the Lewis lung tumor model and an insoluble 20 *E. coli* derived form of this protein was shown to be efficacious in preventing primary tumor growth in several tumor models (O'Reilly et al., *Cell* **88**: 277-285, 1997; Boehm et al., *Nature* **390**: 404-410, 1997).

Purification and refolding of endostatin

Although many types of expression systems have been developed over the 25 past twenty years, bacterial systems, particularly those based on *E. coli*, are widely used for the production of proteins on an industrial scale. Vectors which permit high level expression and the ability to carry out fermentations at high cell densities and low cost, have contributed to the extensive development and use of *E. coli*-based expression systems. One significant problem, however, is the tendency 30 of *E. coli* to form inclusion bodies which contain the desired recombinant protein. Inclusion body formation necessitates additional downstream processing, such as *in vitro* refolding, before biologically active proteins can be recovered. The

- 4 -

tendency to form insoluble aggregates does not appear to correlate with factors such as size, hydrophobicity, subunit structure, or the use of fusion domains (Kane J.F. and Harley, D.L., *Tibtech* **6**: 95, 1988). Inclusion body formation appears to be determined by the rates of protein synthesis, folding, aggregation, and proteolytic degradation, the solubility and thermodynamics of folding intermediates and native proteins, and the interactions of these species with chaperone proteins (Rainer Rudolph, *In Protein Engineering: Principles and Practice*, Edited by Jeffrey L. Cleland and Charles S. Craik, p 283-298, Wiley-Liss, Inc., New York, New York, 1996).

Inclusion bodies generally form in the cytoplasm of cells expressing a recombinant protein at high levels. They refract light when observed by phase contrast microscopy and thus are sometimes referred to as refractile bodies. The inclusion bodies are characterized by a relatively high specific density and can be pelleted from lysed cells by centrifugation. The formation of inclusion bodies may protect recombinant proteins from proteolysis as they do not easily disintegrate under physiological solvent conditions. High concentrations of denaturants, such as 6 M guanidine hydrochloride or 6-8 M urea, have been commonly used to solubilize the proteins present in inclusion bodies. A variety of inclusion body solubilization protocols have been compared (Fisher, B., Summer, L. and Goodenough, P. *Biotechnol. Bioeng.* **1**: 3-13, 1992).

Although the desired foreign gene product is the main component of inclusion bodies, other host cell proteins such as small heat shock proteins, outer membrane proteins, elongation factor EF-Tu, and RNA polymerase may also be enriched in such preparations (Allen, S.P., Polazzi, J.O. Gierse, J.K., and Easton, A.M., *J. Bacteriol.* **174**: 6938-6947, 1992); Hart, R.A., Rinas, U., and Bailey, J.E., *J. Biol. Chem.* **265**: 12728-12733, 1990; Hartley, D.L., and Kane, J.F., *Biochem. Soc. Trans.* **16**: 101, 1988).

World patent application WO 97/15666 describes the expression, purification, and characterization of endostatin from *E. coli* and baculovirus-infected insect cells. The bacterially-derived endostatin was not refolded into its native state, but was utilized as an insoluble suspension for most of these studies. This disclosure also describes the purification of native endostatin from conditioned media of the murine hemangioendothelioma cell line EOMA.

- 5 -

Endostatin was purified from this conditioned media through classical purification methodology.

No successful attempts at refolding endostatin have been described (O'Reilly et al., *Cell* **88**: 277-285, 1997). The *E. coli*-derived recombinant endostatin characterized by these authors precipitated following dialysis against PBS. The precipitated (nonrefolded) material could not be tested *in vitro* because of its insolubility in culture media. A small (unspecified) percentage of the material spontaneously solubilized in the PBS during dialysis. This material had comparable inhibitory activity in endothelial cell activities as both native and soluble baculovirus-derived endostatin. When the *E. coli*-derived recombinant endostatin was refolded in the presence of 0.1 M sodium phosphate, pH 7.4, 150 mM NaCl, 0.6M urea, 2 mM reduced glutathione, 0.02 mM oxidized glutathione, and 0.5 M arginine at a final concentration of 0.1 mg/ml, over 99% of the protein was lost. This great loss precluded use of this material for *in vivo* assays. Instead, the authors used the uncharacterized insoluble (nonrefolded) form of endostatin for most of their *in vivo* studies. The *E. coli*-derived endostatin precipitate was observed to dissolve gradually over five days and produce a sustained anti-angiogenic effect in chick chorioallantoic membrane (CAM) assays. A suspension of the same material formed a pellet at the site of injection in mice, which resorbed slowly over a 24-48 hour period.

Subsequent studies by the same group demonstrated that drug resistance does not develop when mice bearing lung carcinoma, T241 fibrosarcoma, or B16F10 melanoma are treated with mouse endostatin (Boehm, T., et al., *Nature* **390**: 404-407, 1997). *E. coli*-derived recombinant murine endostatin was prepared as described earlier (O'Reilly et al., *Cell* **88**: 277-285, 1997) except that bacteria were pelleted and resuspended in 8 M urea, 10 mM beta mercaptoethanol, and 10 mM pH 8.0, and incubated for 1 to 2 hours. Beta mercaptoethanol was eliminated in subsequent steps. Recombinant mouse endostatin was delivered to mice as a suspension in PBS. Mice bearing one of the three tumor types were injected with the purified but poorly soluble endostatin suspension into the subcutaneous dorsa at a site remote from the inoculated tumors. Treatment was stopped when tumors regressed, then allowed to regrow. Tumor growth did not recur after 6, 4, or 2 endostatin treatment cycles, respectfully, when therapy was ended.

- 6 -

Recently, the circulating form of human endostatin was isolated and characterized (Standker et al., *FEBS Letters* **420**: 129-133, 1997). High molecular weight peptides (1—20 kDa) were isolated from 2,500 liters of human blood ultrafiltrate (hemofiltrate, HF) obtained from patients with chronic renal insufficiency. Extracts were bound to a preparative cation exchange column and eluted by pH pool fractionation (7 buffers with pH increasing from 3.6 to 9.0). High molecular weigh peptides were detected in pool 8, which was eluted with water, and subsequently purified by reversed-phase HPLC. Aliquots were subjected to matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and the exact molecular mass determined by electrospray mass spectroscopy (ES-MS) was found to be 18,494 Da. Cysteine residues 1-3 and 2-4 in the molecule were found to be linked by disulfide bridges. The final recovery during purification was estimated to be in the range of 20%, resulting in a concentration of $>10^{-11}$ M in hemofiltrate. The resulting concentration of endostatin in patient plasma was estimated to be in the range of 10^{-10} M or higher. It is not known if pool of tissue bound endostatin exists, as was proposed for angiostatin (Kost et al., *Eur J. Biochem.* **236**: 682-688, 1996). *In vitro* biological characterization of the native human endostatin (which was 12 amino acids shorter than mouse endostatin) showed no anti-proliferative activity on different endothelial cell types. The characterization of recombinant forms of human endostatin was not reported. The authors speculate that differences in reported activity of mouse and human forms of endostatin could be due to several factors: (i) the two forms may have been isolated from different sources and may have different selectivity, specificity, or efficacy in *in vitro* and *in vivo* assays. (ii) Differences in post-translational modifications found on the peptides may account for the discrepancy in reported activities. (iii) Human endostatin may not necessarily inhibit proliferation of endothelial cells, but indirectly influence other cellular components which are observable only in a complex *in vivo* system.

Summary of the Invention

One object of the invention is to describe a method for expressing high levels of endostatin in bacteria.

- 7 -

Another aspect of the invention is to describe an efficient method by which endostatin inclusion bodies can be solubilized, subsequently refolded, and purified to generate biologically-active material.

Preferably the steps of solubilizing mouse or human endostatin inclusion bodies are carried out at an elevated pH. Preferably the elevated pH in the solubilizing step is carried out at a pH ranging from about pH 9 to about pH 11.5. Even more preferably the elevated pH range is from about pH 10 to about pH 11. Most preferably, the elevated pH is about 10.5.

Preferably the steps of refolding mouse or human endostatin inclusion bodies are carried out at a near-neutral pH. Preferably the near-neutral pH in the solubilizing step is carried out at a pH ranging from about pH 6 to about pH 8.5. Even more preferably the near-neutral pH range for refolding mouse endostatin is from about pH 7.0 to about pH 8.0. Most preferably, near-neutral pH range for refolding mouse endostatin is about pH 7.5. Even more preferably the near-neutral pH range for refolding human endostatin is from about pH 7.0 to about pH 8.0. Most preferably, near-neutral pH range for refolding human endostatin is about pH 7.5.

Preferably, the concentration of endostatin gene product is present at a concentration of from about 0.2 to about 20 mg/ml during the solubilization step. Even more preferably, the concentration is about 2.5 mg/ml.

Preferably, the concentration of endostatin gene product is present at a concentration of from about 0.02 to about 2 mg/ml during the refolding step. Even more preferably, the concentration is about 0.25 mg/ml.

Preferably a denaturant selected from urea and guanidine hydrochloride is used during the solubilization and refolding steps. Even more preferably, the denaturant is urea.

Preferably the concentration of urea is from about 4 M to about 10 M during the solubilization step. Even more preferably, the concentration is about 6 M.

Preferably the concentration of urea is from about 2 M to about 4 M during the refolding step. Even more preferably, the concentration is about 3.5 M.

- 8 -

Preferably the concentration of guanidine hydrochloride is from about 2 M to about 8 M during the solubilization step. Even more preferably, the concentration is about 4 M.

5 Preferably the concentration of guanidine hydrochloride is from about 0.2 M to about 2 M during the refolding step. Even more preferably, the concentration is about 1.5 M.

10 Preferably, the solubilization and reducing steps are carried out in the presence of a reducing agent capable of reducing disulfide linkages to sulphydryl groups. Preferably the reducing agent is selected from the group consisting of DTT, BME, cysteine, and reduced glutathione. Even more preferably, the reducing agent is DTT or cysteine.

Preferably, DTT is present at a concentration of from about 2 mM to about 10 mM during the solubilization step. Even more preferably, the concentration is about 5 mM.

15 Preferably, DTT is present at a concentration of from about 0.5 mM to about 2 mM during the refolding step. Even more preferably, the concentration is about 0.5 mM.

20 Preferably, reduced glutathione is present at a concentration of from about 5 mM to about 20 mM during the solubilization step. Even more preferably, the concentration is about 10 mM.

Preferably, reduced glutathione is present at a concentration of from about 0.5 mM to about 4 mM during the refolding step. Even more preferably, the concentration is about 1mM.

25 Preferably, cysteine is present at a concentration of from about 5 mM to about 20 mM during the solubilization step. Even more preferably, the concentration is about 10 mM.

Preferably, cysteine is present at a concentration of from about 0.5 mM to about 4 mM during the refolding step. Even more preferably, the concentration is about 1 mM.

- 9 -

Preferably, an agent capable of enhancing the interchange of disulfide bonds is present during the refolding step. Preferably the agent is selected from cystine and oxidized glutathione. Even more preferably, the agent is cystine.

5 Preferably, cystine is present at a concentration of from about 0.2 mM to about 5 mM during the refolding step. Even more preferably, the concentration is about 1 mM.

10 Preferably disulfide bonds are formed through air oxidation during the refolding step. Preferably, the air oxidation step is carried out from about 12 to about 96 hours. Even more preferably, the air oxidation step is carried out from about 24 to about 72 hours. Most preferably the air oxidation step is carried out about 60 hours.

15 Preferably refolded endostatin is further purified by a process selected from but not limited to the group consisting of ion-exchange chromatography, hydrophobic interaction chromatography and RP-HPLC.

20 Preferably the method of expression, solubilization, refolding and purification uses endostatin genes that are either mouse or human. Even more preferably these genes are selected from the group consisting of SEQ ID NOs: 5-9.

25 Novel proteins of this invention are modified human or mouse endostatin amino acid sequences, and said protein can optionally be immediately preceded by (methionine⁻¹), (alanine⁻¹), (methionine⁻², alanine⁻¹), (serine⁻¹), (methionine⁻², serine⁻¹), (cysteine⁻¹), or (methionine⁻², cysteine⁻¹).

30 Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding endostatin, variants and muteins of endostatin, related microbial and eukaryotic expression systems, and processes for making (comprising the steps of expressing, solubilizing, refolding, purifying) these proteins.

Cloning of DNA sequences encoding these proteins may be accomplished by the use of intermediate vectors. Alternatively, one gene can be cloned directly into a vector containing the other gene. Linkers and adapters can be used for joining the DNA sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest. Thus genetic material (DNA) encoding one

- 10 -

polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism or cell line is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has all or a portion of one protein joined by a linker region to a all or a portion of second protein.

Another aspect of the present invention includes plasmid DNA vectors for use in the expression of these proteins. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms or cell lines capable of expressing the proteins include expression vectors comprising nucleotide sequences coding for the proteins joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the proteins. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and which are capable of directing the replication and expression thereof in selected host cells.

Methods for producing these proteins is another aspect of the present invention. The method of the present invention involves culturing suitable cells or cell lines, which has been transformed with a vector containing a DNA sequence coding for expression of a novel multi-functional protein. Suitable cells or cell lines may be bacterial cells. For example, the various strains of *E. coli* are well-known as host cells in the field of biotechnology. Examples of such strains include *E. coli* strains JM101 (Yanisch-Perron et al., *Gene* **33**: 103-119, 1985) and MON105 (Obukowicz et al., *Applied Environmental Microbiology* **58**: 1511-1523, 1992). Also included in the present invention is the expression of the multi-functional proteins utilizing a chromosomal expression vector for *E. coli* based on the bacteriophage Mu (Weinberg et al., *Gene* **126**: 25-33, 1993). Various strains of *B. subtilis* may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.

- 11 -

When expressed in the *E. coli* cytoplasm, the gene encoding the proteins of the present invention may also be constructed such that at the 5' end of the gene codons are added to encode Met²-Ala⁻¹, Met²-Ser⁻¹, Met²-Cys⁻¹, or Met⁻¹ at the N-terminus of the protein. The N termini of proteins made in the cytoplasm of *E. coli* are affected by post-translational processing by methionine aminopeptidase (Ben Bassat et al., *J. Bacteriol.* **169**:751-757, 1987) and possibly by other peptidases so that upon expression the methionine is cleaved off the N-terminus. The proteins of the present invention may include polypeptides having Met⁻¹, Ala⁻¹, Ser⁻¹, Cys⁻¹, Met²-Ala⁻¹, Met²-Ser⁻¹, or Met²-Cys⁻¹ at the N-terminus. These mutant proteins may 5 also be expressed in *E. coli* by fusing a secretion signal peptide to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process.
10

Definitions

The following is a list of abbreviations and the corresponding meanings as used interchangeably herein:

15	g = gram(s)
	HPLC = high performance liquid chromatography
	mg = milligram
	ml = milliliter
	DTT = dithiothreitol
20	RT = room temperature
	PBS = phosphate buffered saline

The following is a list of definitions of various terms used herein:

The term "anti-tumor" means possessing an activity which slows or abolishes the growth of, or which kills, or otherwise harms tumors *in vivo*.

25 The term "native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

30 The terms "mutant amino acid sequence," "mutant protein", "variant protein", "mutein", or "mutant polypeptide" refer to a polypeptide having an amino acid sequence which varies from a native sequence due to amino acid additions, deletions, substitutions, or any combination thereof, or is encoded by a nucleotide

- 12 -

sequence from an intentionally-made variant derived from a native sequence or chemically synthesized.

The term "endostatin" means a protein fragment of collagen XVIII having anti-angiogenic activity. The activity of said fragments can be determined by the mouse corneal micropocket assay of angiogenesis or by inhibition of endothelial cell growth or migration *in vitro*. Preferably, mouse endostatin means the sequence depicted in SEQ ID 10, and human endostatin means the sequence depicted in SEQ ID NO 11.

Brief Description of the Figures

10 **Figure 1 shows a schematic of the cloned endostatin fragment**

The C-terminal fragment of collagen XVIII is shown. Plasmid pMON24345 (SEQ ID NO: 8) encodes the C-terminal fragment of mouse collagen XVIII, Plasmid pMON20440 (SEQ ID NO: 9) encodes the C-terminal fragment of human collagen XVIII.

15 **Figure 2 shows a schematic of the endostatin refolding procedure**

Optimal solubilization conditions in the presence of urea and DTT or cysteine and refolding in the presence of cystine are outlined.

Figure 3 shows mouse endostatin refold products under varying pH conditions

20 RP-HPLC tracings of mouse endostatin refold products at pH 7.5, pH 8.0, and pH 8.5 in 3.5 M urea.

Figure 4 shows mouse endostatin refold products under varying urea concentrations

25 RP-HPLC tracings of mouse endostatin refold products at 3.0, 3.5, and 4.0 M urea at pH 7.5.

- 13 -

Figure 5 shows human endostatin refold products under varying pH conditions

RP-HPLC tracings of human endostatin refold products at pH 7.5, pH 8.0, and pH 7.5 in 3.5 M urea.

5 **Figure 6 shows human endostatin refold products under varying urea concentrations**

RP-HPLC tracings of human endostatin refold products at 3.0, 3.5, and 4.0 M urea at pH 7.5..

Figure 7 shows the inhibition of HMEC migration by mouse endostatin

10 Purified mouse endostatin assayed in the HMEC cell migration assay at 15 and 30 ug/ml. Inhibition of migration was observed at both concentrations.

Figure 8 shows the inhibition of CPAE migration by mouse endostatin

Purified mouse endostatin was assayed for inhibition of CPAE migration at 5 and 30 ug/ml. Inhibition of migration was observed at both concentrations.

15 **Figure 9 shows the inhibition of endothelial cell proliferation by mouse endostatin.**

Inhibition of endothelial cell proliferation by mouse endostatin. Significant inhibition was observed at 20 ug/ml.

20 **Figure 10 shows the inhibition of endothelial cell proliferation by human endostatin.**

Inhibition of endothelial cell proliferation by human endostatin. Significant inhibition was observed at 10 ug/ml of endostatin.

Detailed description of the invention

25 The following examples will illustrate the invention in greater detail, although it will be understood that the invention is not limited to these specific

- 14 -

examples. Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

5 **General methods**

General methods of cloning, expressing, and characterizing proteins are found in T. Maniatis, et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1982, and references cited therein, incorporated herein by reference; and in J. Sambrook, et al., *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory, 1989, and references cited therein, incorporated herein by reference.

10 Unless noted otherwise, all specialty chemicals were obtained from Sigma, Co. (St. Louis, MO). Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beverly, MA) or Boehringer Mannheim (Indianapolis, IN) or Promega (Madison, WI).

15 **Strains and plasmids**

The bacterial strains used in these studies are listed in Table 1. Plasmids used in or constructed for this study are listed in Table 2.

20 **Transformation of *E. coli* strains**

25 *E. coli* strains (Table 1), such as DH5 alpha and DH10B (Life Technologies, Rockville, MD), and TG1 (Amersham Corp., Arlington Heights, IL) are used for transformation of ligation reactions and are the hosts used to prepare plasmid DNA for transfecting mammalian cells. *E. coli* strains, such as JM101 (Yanisch-Perron et al., *Gene*, 33: 103-119, 1985) and MON105 (Obukowicz, et al., *Appl. and Envir. Micr.*, 58: 1511-1523, 1992) can be used for expressing the proteins of the present invention in the cytoplasm or periplasmic space.

DH5 alpha and DH10B subcloning efficiency cells are purchased as competent cells and are ready for transformation using the manufacturer's protocol. *E. coli* strains JM101 AND MON105 are rendered competent to take up

- 15 -

DNA using a CaCl_2 method. Typically, 20 to 50 mL of cells are grown in LB medium (1% Bacto-tryptone, 0.5% Bacto-yeast extract, 150 mM NaCl) to a density of approximately 1.0 absorbance unit at 600 nanometers (OD600) as measured by a Baush & Lomb Spectronic spectrophotometer (Rochester, NY). The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCl_2 solution [50 mM CaCl_2 , 10 mM Tris-Cl ((10 mM 2-amino-2-(hydroxymethyl) 1,3-propanediol hydrochloride, pH7.4] and are held at 4°C for 30 minutes. The cells are again collected by centrifugation and resuspended in one-tenth culture volume of CaCl_2 solution. Ligated DNA is added to 0.2 mL of these cells, and the samples are held at 4°C for 30-60 minutes. The samples are shifted to 42°C for two minutes and 1.0 mL of LB is added prior to shaking the samples at 37°C for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% Bacto-agar) containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants. The plates are incubated overnight at 37°C.

Colonies are picked and inoculated into LB plus appropriate antibiotic (100 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37°C while shaking.

20 **DNA isolation and characterization**

Plasmid DNA can be isolated by a number of different methods and using commercially available kits known to those skilled in the art. Plasmid DNA is isolated using the Promega Wizard™ Miniprep kit (Madison, WI), the Qiagen QIAwell Plasmid isolation kits (Chatsworth, CA) or Qiagen Plasmid Midi or Mini kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, cells are pelleted by centrifugation (5000 x g), the plasmid DNA released with sequential NaOH/acid treatment, and cellular debris is removed by centrifugation (10000 x g). The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the column is washed, and plasmid DNA eluted. After screening for the colonies with the plasmid of interest, the *E. coli* cells are inoculated into 50-100 ml of LB plus appropriate antibiotic for overnight growth at 37°C in an air incubator while shaking. The purified plasmid DNA is used for DNA sequencing, further restriction enzyme digestion, additional

- 16 -

subcloning of DNA fragments and transfection into *E. coli*, mammalian cells, or other cell types.

Sequence confirmation

Purified plasmid DNA is resuspended in deionized H₂O and its concentration is determined by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISM™ DyeDeoxy™ terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, CA) kits (Part Number 401388 or 402078) according to the manufacturer's suggested protocol, usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are performed in a DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) following the recommended amplification conditions. Samples are purified to remove excess dye terminators with Centri-Sep™ spin columns (Princeton Separations, Adelphia, NJ) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75% polyacrylamide-8M urea gels using ABI Model 373A and Model 377 automated DNA sequencers. Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher DNA analysis software (Gene Codes Corporation, Ann Arbor, MI).

20 Small-scale expression of endostatin in *E. coli*

E. coli strain MON105 or JM101 harboring the plasmid of interest is grown at 37°C in M9 plus casamino acids medium with shaking in an air incubator Model G25 from New Brunswick Scientific (Edison, NJ). Growth is monitored at OD₆₀₀ until it reaches a value of 1.0, at which time nalidixic acid (10 mg/mL) in 0.1 N NaOH is added to a final concentration of 50 µg/mL. The cultures are then shaken at 37°C for three to four additional hours. A high degree of aeration is maintained throughout the culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (IB). One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al., "Molecular

- 17 -

Cloning: A Laboratory Manual", 1982). The culture is centrifuged (5000 x g) to pellet the cells.

Large (10L)-scale expression of endostatin in *E. coli*

The Endostatin molecules were all scaled up in a 10 L Biostat E™ fermenter (B. Braun Biotech Inc., Allentown PA). The fermentation medium used was M9 salts supplemented with 2% casamino acids (Difco Laboratories, Detroit MI) and glucose. Approximately one milliliter of a thawed culture was transferred to a 3.8 L Fernbach shake flask containing 1.0 L of medium and then incubated at 37°C at a shaker speed of 250 rpm for 12 hours. This shake flask culture was then used to inoculate a 10 L fermenter containing 9.0 L of medium. The fermentation conditions were as follows: agitation = 1000 rpm, sparger airflow rate = 15 liters/min, pH control = 7.0 by the addition of NH₄OH, backpressure = 10 psi, dissolved oxygen control > 30%, and temperature = 37°C. Glucose was initially batched in at 15 g/l and controlled at 2-5 g/l by the addition of a 50% glucose feed stock. The fermentation culture was grown to an initial OD (550 nm) = 12-15 and induced with 50 mg/l nalidixic acid. The fermentation was harvested four hours post induction by continuous-flow centrifugation.

10L scale inclusion body isolation

The cell paste from a 10L fermentation was resuspended in approximately 6.0 L of 50mM Tris/ 150 mM EDTA buffer. The resuspension was passed once through a microfluidizer® (Newton, MA) at 10,000 psi and temperature maintained under 8°C. The recovered homogenate was then spun at 15,000 x G for 25 minutes and mixed to consistency with an Ultr-Turrax mixer. The cell paste resuspension was then homogenized by passing the cell suspension two times through a Microfluidizer™ (Newton, MA) operating at 10,000 psi pressure. The temperature of the homogenate was maintained less than 6°C by collection in a stainless steel container placed in an ice bath. Inclusion bodies were then isolated by centrifugation of the cell homogenate at 15,000 x g for 30 minutes and removal of supernatant. Inclusion bodies were then washed a total of two times by resuspending the inclusion bodies in chilled D.I. and centrifugation at 15,000 x g for 30 minutes. Endostatin inclusion bodies were then frozen at -70°C.

- 18 -

Small-scale isolation of inclusion bodies

The cell pellet from a 330 mL *E. coli* culture is resuspended in 15 mL of sonication buffer (50 mM Tris-HCl, pH 8.0, 1 mM EDTA). These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disruptor (Model W-375, 5 Heat Systems-Ultrasonics, Inc., Farmingdale, New York). Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies (IB). The first round of sonication is a 3 minute burst followed by a 1 minute burst, and the final two rounds of sonication are for 1 minute each.

10 **Extraction and refolding of human and mouse proteins from inclusion body pellets**

All steps are at 4°C. Mouse endostatin inclusion bodies were dissolved in 6M urea, 5 mM DTT, 50 mM Bis-Tris Propane, pH 10.8 at 2.5 mg/ml endostatin. This solution was stirred for 2 hours and followed by addition of cystine (stock 0.2 15 M, pH 10.5) to 10 mM. This was mixed for 5 minutes and then diluted to 0.25 mg/ml endostatin in 3.5 M urea, 100 mM Bis-Tris propane, pH 7.0. It was then stirred for 60 hours to complete the refolding of the protein as assessed by reverse-phase HPLC.

20 Human endostatin inclusion bodies were dissolved in 10 mM cysteine, 6M urea, 50 mM Bis-Tris propane, pH 10.8, at 2.5 mg/ml endostatin. This was stirred for 2 hours followed by addition of 10 mM cystine (stock 0.2 M, pH 10.5) and mixed for 5 minutes. This solution was then diluted to 0.25 mg/ml endostatin in 3.0 M urea, 100 mM Bis-Tris propane, pH 7.5 and stirred for 60 hours to complete the refolding step.

25 **Purification**

Purification of mouse or human endostatin was achieved using the same process using acid precipitation followed by column chromatography on a sulfo-propyl-column. The refolded sample was concentrated approximately 10-fold by ultrafiltration and the pH lowered to pH 5.0 with acetic acid. This was then 30 dialyzed extensively against 5 mM acetic acid, pH 5.0. The precipitate was removed by filtration and the filtrate applied to a Pharmacia S-Sepharose HP

- 19 -

column. The column was washed with 1 column volume of equilibrating buffer and the protein eluted using a 20 column volume gradient of 50 mM phosphate, pH 6.5 to the same buffer containing 0.4 M NaCl. Fractions were analyzed by SDS-gel electrophoresis and RP-HPLC and pooled and dialyzed against PBS and frozen.

5 In some cases the folded proteins can be affinity-purified using affinity reagents such as monoclonal antibodies or receptor subunits attached to a suitable matrix. Purification can also be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic interaction chromatography or reversed phase HPLC. These and other protein
10 purification methods are described in detail in Methods in Enzymology, Volume 182 "Guide to Protein Purification," edited by Murray Deutscher, Academic Press, San Diego, California, 1990.

Protein characterization

15 The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, amino acid sequencing and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

Endothelial cell proliferation assay

20 The endothelial cell proliferation assay was performed as described by Cao et al. (*J. Biol. Chem.* 271: 29461-29467, 1996). Briefly, human dermal microvascular endothelial cells (HdMVEC, Clonetics) or bovine adrenal cortex microvascular endothelial cells (BacEnd, Incell, San Antonio, TX) were maintained in MCDB131 containing 5% heat-inactivated fetal bovine serum (FBS, Hyclone),
25 antibiotics, 100 ug/ml heparin (Sigma) and 100 ug/ml endothelial mitogen (Biomedical Technologies). Confluent monolayers at passages 2-5 were dispersed in 0.05% trypsin and resuspended in complete medium. Five hundred ul of complete media containing 1.25×10^4 cells were seeded into wells of a 24-well tissue culture plate coated with 0.1% gelatin (Sigma). The cells were incubated
30 overnight at 37°C/5% CO₂ at which time the media was replaced with 250 ul of media containing 5% FBS and various concentrations of inhibitors. After 30

- 20 -

minutes of incubation, 250 ul of media containing 1 ng/ml bFGF (R&D Systems) was added and the cells were incubated for an additional 72 hours, at which time they were trypsinized and counted with a Coulter counter.

Endothelial cell migration assay

5 The endothelial cell migration assay is performed essentially as previously described (Gately et al., *Cancer Res.* **56**:4887-4890, 1996). To determine the ability of endostatin to inhibit the migration of endothelial cells, migration assays were performed in a transwell chamber (Costar) containing 8 mm pore size polycarbonate membranes. The cells utilized in the assay were either human
10 microvascular endothelial cells (Emory University, Atlanta, GA) or bovine pulmonary artery endothelial cells (Monsanto, St. Louis, MO). The cells were starved overnight before use in MCDB131 + 0.1% BSA (human cells) or DMEM + 0.1%BSA (bovine cells), harvested, and resuspended in the same media at 10^6 cells/ml. The lower side of the transwells were coated with 0.1% gelatin for 30
15 minutes at 37°C before addition of 2×10^5 cells to the upper chamber. The transwell was moved to a well containing the chemoattractant (bFGF or VEGF) in the lower chamber. Migration was allowed to occur overnight at 37°C. The membranes were then fixed and stained, and the number of cells that migrated to the lower side of the membrane counted in 3 high powered fields.

20 **Example 1: Construction of pMON24345 (SEQ ID NO: 8) and selection of strains producing high levels of mouse endostatin**

25 Total mouse RNA (Clontech Laboratories Inc, Palo Alto, CA), 5 ug, was mixed with 500 ng of random hexamer primer (Promega Corporation, Madison, WI), heated for 10 min at 65°C, then cooled for 2 min on ice. To the RNA/primer mixture was added 20 units of Rnasin (Promega), SuperScript II buffer, DTT to a final concentration of 0.01 M, dNTP mix (Boehringer) to a final concentration of 0.005 M and 200 units of SuperScript II transcriptase (Life Technologies Inc.). The reaction was incubated at 42°C for 1.5 hours and the enzyme was inactivated by incubating the reaction at 70°C for 5 min. RNA was removed by adding 2 units of *E. coli* RNase H (Life Technologies Inc.) and incubating the reaction at 37°C for 20
30 min. Double-stranded DNA was generated by polymerase chain reaction with the addition of dNTPs to a final concentration of 1.6 mM, 50 pmol of 5 prime mouse

- 21 -

endostatin primer (SEQ ID NO: 1), 50 pmol of 3 prime mouse endostatin primer (SEQ ID NO: 2), High Fidelity PCR buffer, and 2.5 units of High-Fidelity enzyme (Boehringer). The reaction mixture was incubated at 95°C for 3 min, then cycled 10 times through a 15 second 94°C incubation, a 30 second 50°C incubation, a 4 min. 72°C incubation, then cycled 15 times through a 15 second 94°C incubation, 30 second 50°C incubation, 4 min plus 20 second extension per cycle 72°C incubation. Finally the reaction was incubated at 72°C for 7 min.

Double-stranded DNA was subcloned into the pCRII vector (Invitrogen) by adding 1 ul of the PCR reaction to 25 ng of vector, 1 unit of T4 ligase in the ligation buffer. The ligase reaction was incubated at 12°C overnight. The ligated DNA was transformed into DH5 alpha competent cells (Life Technologies Inc., Rockville, MD) and grown on LB amp plates. Two isolates with inserts as determined by *Eco*RI digestion were further characterized. The cDNA inserts of the two isolates, pMON24342 (SEQ ID NO: 5) and pMON24343 (SEQ ID NO: 6), were analyzed by DNA sequencing using standard dideoxy technology. To construct the correct coding DNA sequence both pMON24342 and pMON24343 were digested with *Apa*I. The *Apa*I mouse endostatin DNA fragment and the pMON24342 vector plus 5 prime mouse endostatin coding DNA sequence were isolated using the Qiaex II Gel Extraction Kit (Qiagen, Germany). The fragments were ligated together in 50 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 50 ug/ml BSA and 1 unit T4 ligase. The reconstructed plasmid was transformed into DH5 alpha competent cells to generated pMON24344 (SEQ ID NO: 7). The plasmid pMON24344 was digested with *Nco*I and *Hind*III and the fragment isolated with Qiaex II Gel Extraction Kit. The pMON24344 *Nco*I/*Hind*III fragment with ligated into a *Nco*I/*Hind*III-digested dephosphorylated pMON5723 *E. coli* expression vector in 50 mM tris pH 7.5, 10 mM MgCl₂, 50 ug/ml BSA and 1 unit of T4 ligase. The ligated DNA was transformed into MON105 and isolates selected on Spec LB plates to generate pMON24345 (SEQ ID NO: 8). *E. coli* strain MON105 harboring pMON24345 was induced with 10 mg/ml nalidixic acid and mouse endostatin expressed in these cells was monitored by SDS-PAGE.

- 22 -

Example 2: Construction of pMON 20440 (SEQ ID NO: 9) encoding human endostatin

Total human RNA (Clontech Laboratories Inc, Palo Alto, CA), 5 ug, was mixed with 500 ng of random hexamer primer, heated for 10 min at 65°C then cooled for 2 min on ice. To the RNA/primer mixture was added 20 units of Rnasin (Promega), SuperScript II buffer, DTT to a final concentration of 0.01 M, dNTP mix (Boehringer) to a final concentration of 0.005 M and 20 units of SuperScript II transcriptase. The reaction was incubated at 42°C for 1.5 hours and the enzyme was inactivated by incubating the reaction at 70°C for 5 min. RNA was removed by adding 2 units of *E. coli* RNase H and incubating the reaction at 37°C for 20 min. Double-stranded DNA was generated by polymerase chain reaction with the addition of dNTPs to a final concentration of 1.6 mM, 50 pmol of 5 prime human endostatin primer (SEQ ID NO: 3), 50 pmol of 3 prime human primer (SEQ ID NO: 4), High-Fidelity PCR buffer, and 2.5 units of High-Fidelity enzyme (Boehringer). The reaction mixture was incubated at 95°C for 3 min, then cycled 10 times through a 15 second 94°C incubation, a 30 second 50°C incubation, a 4 min 72°C incubation, then cycled 15 times through a 15 second 94°C incubation, 30 second 50°C incubation, 4 min plus 20 second extension per cycle 72°C incubation. Finally the reaction was incubated at 72°C for 7 min.

The double stranded DNA was digested with *Nco*I and *Hind*III and ligated into a *Nco*I/*Hind*III digested dephosphorylated pMON2341 *E. coli* expression vector in 50 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 50 ug/ml BSA and 1 unit of T4 ligase. The ligated DNA was transformed into *E. coli* strain MON105 and isolates selected on Amp LB plates to generate pMON20440 (SEQ ID NO: 9). *E. coli* strain MON105 harboring pMON20440 was induced with 10 mg/ml nalidixic acid and human endostatin expressed in these cells was monitored by SDS-PAGE.

Example 3: Method for refolding mouse endostatin

All steps are at 4°C. Mouse endostatin inclusion bodies were dissolved in 6M urea, 5 mM DTT, 50 mM Bis-Tris Propane, pH 10.8 at 2.5 mg/ml. This solution was stirred for 2 hours and followed by addition of cystine (stock 0.2 M, pH 10.5) to 10 mM. This was mixed for 5 minutes and then diluted to 0.25 mg/ml endostatin in 3.5 M urea, 100 mM Bis-Tris propane, pH 7.0. It was then stirred for 60 hours

- 23 -

to complete the refolding of the protein as assessed by reverse-phase HPLC. Other pH conditions and urea concentrations can be used, but at lower efficiency. Figures 3 and 4 show HPLC tracings of mouse endostatin refold products under varying pH conditions and urea concentrations, respectively. Figures 7, 8, and 9 show inhibitory activity of purified mouse endostatin in endothelial cell proliferation and cell migration assays.

Example 4: Method for refolding human endostatin

All steps are at 4°C. Human endostatin inclusion bodies were dissolved in 10 mM cysteine, 6M urea, 50 mM Bis-Tris propane, pH 10.8, at 2.5 mg/ml endostatin. This was stirred for 2 hours followed by addition of 10 mM cystine (stock 0.2 M, pH 10.5) and mixed for 5 minutes. This solution was then diluted to 0.25 mg/ml endostatin in 3.0 M urea, 100 mM Bis-Tris propane, pH 7.5 and stirred for 60 hours to complete the refolding step. Other pH conditions and urea concentrations can be used, but at lower efficiency. Figures 5 and 6 show HPLC tracings of human endostatin refold products under varying pH conditions and urea concentrations, respectively. Figure 10 shows inhibitory activity of purified human endostatin in an endothelial cell proliferation assay.

Those skilled in the art will recognize that the solubilization, refolding, and purification conditions outlined above represent dramatic improvements over published methods for purifying endostatin from bacteria. Production of endostatin on a commercial scale for use in preclinical studies and clinical trials will require vast amounts of soluble properly-refolded material which possesses the desired biological characteristics. Commercial development of endostatin as a therapeutic product requires thoroughly-characterized material that behaves the same in all applications. Soluble, properly-refolded endostatin, therefore, is more desirable than suspensions of insoluble material for *in vitro* assays and for *in vivo* studies of the effectiveness, potency, pharmacokinetics, and pharmacodynamics of this protein. The dramatically-improved process for expressing, solubilizing, refolding, purifying, and characterizing this material outlined in this disclosure will greatly facilitate subsequent studies aimed at developing endostatin, endostatin-fragments, muteins, inserteins, permuteins, or chimeras thereof, or conjugates of these with other anti-angiogenic proteins or small molecules which

- 24 -

are useful as compounds in the treatment of angiogenesis disorders, including cancer.

All references, patents, or applications cited herein are incorporated by reference in their entirety, as if written herein.

- 25 -

Tables

Table 1: Strains

Designation	Description or Genotype	Reference/Source
DH5 α TM	F, <i>phi</i> 80 <i>dlacZ</i> <i>delta</i> M15, <i>delta</i> (<i>lacZYA-argF</i>)U169, <i>deoR</i> , <i>recA1</i> , <i>endA1</i> , <i>hsdR17</i> (rk ⁺ ,mk ⁺), <i>phoA</i> , <i>supE44</i> , <i>lambda-</i> , <i>thi-1</i> , <i>gyrA96</i> , <i>relA1</i>	Life Technologies, Rockville, Maryland
DH10B	F <i>mcrA</i> Δ (<i>mrr-hsdRMS-mcrBC</i>) ϕ <i>dlacZ</i> Δ M15 Δ <i>lacX74</i> <i>deoR</i> <i>recA1</i> <i>endA1</i> <i>araD139</i> Δ (<i>ara</i> , <i>leu</i>)7697 <i>galU</i> <i>galK</i> λ <i>rpsL</i> <i>nupG</i>	Life Technologies, Rockville, Maryland
JM101 (ATCC # 33876)	delta (<i>pro lac</i>), <i>supE</i> , <i>thi</i> , F'(<i>traD36, proA⁺B⁺, lacI^q</i> , <i>lacZ</i> <i>delta</i> M15)	Yanisch-Perron, et al., <i>Gene</i> , 33: 103-119, 1985
MON105 (ATCC # 55204)	F, <i>lambda</i> -IN (<i>rrnD, rrnE</i>)1, <i>rpoD</i> ⁺ , <i>rpoH358</i>	Obukowicz, et al., <i>Appl. and Envir. Micr.</i> , 58: 1511-1523, 1992
TG1	delta(<i>lac-pro</i>), <i>supE</i> , <i>thi-1</i> , <i>hsdD5/F'</i> (<i>traD36, proA⁺B⁺, lacI^q</i> , <i>lacZ</i> <i>delta</i> M15)	Amersham Corp., Arlington Heights, Illinois

- 26 -

Table 2: Plasmids

Plasmid	SEQ ID NO.	Marker	Description	Source
pMON2341		Amp ^R	Generic Amp-resistant <i>E. coli</i> expression vector containing the <i>E. coli recA1</i> promoter and G10L ribosome binding site, chloramphenicol acetyl transferase gene (cat3) gene and ori M13	Lab collection
pMON5723		Spec ^R	Generic Spec-resistant <i>E. coli</i> expression vector containing the <i>E. coli recA1</i> promoter and G10L ribosome binding site	(Olins and Rangwala, <i>Methods Enzymol.</i> 185 (Gene Expression Technol.): 115-119, 1990)
pCRII		Amp ^R	Commercial PCR fragment (TA) cloning vector	Invitrogen
pMON24342	#5	Amp ^R	pCR II (TA) cloning vector + PCR fragment encoding mouse endostatin, including the native mouse collagen XVIII C-terminal region. <i>Eco</i> RI fragment in pCRII (Amino acids 1104-1288)	This work

- 27 -

pMON24343	#6	Amp ^R	pCR II (TA) cloning vector + PCR fragment encoding mouse endostatin, including the native mouse collagen XVIII C-terminal region. <i>Eco</i> RI fragment in pCRII (Amino acids 1104-1288)	This work
pMON24344	#7	Amp ^R	pCR II (TA) cloning vector + PCR fragment encoding mouse endostatin, including the native mouse collagen XVIII C-terminal region. <i>Eco</i> RI fragment in pCRII (Amino acids 1104-1288)	This work
pMON24345	#8	Spec ^R	pMON5723 <i>Nco</i> I/ <i>Hind</i> III + <i>Nco</i> I/ <i>Hind</i> III fragment of mouse endostatin, including the native mouse collagen XVIII C-terminal region (Amino acids 1104-1288)	This work
pMON20440	#9	Spec ^R	pMON2341 <i>Nco</i> I/ <i>Hind</i> III + <i>Nco</i> I/ <i>Hind</i> III encoding human endostatin, including the native human collagen XVIII C-terminal region	This work

- 28 -

Table 3: SEQ ID Correlation Table

SEQ ID NO:	Sequence	Description
1	gcgccccatggctcatactcatcaggac;	5 prime PCR primer for mouse endostatin
2	gcgcgcaagcttattttggaaaaagagggtcatgaag;	3 prime PCR primer for mouse endostatin
3	GCGCCCCAT GGCTCACAGC CACCGCGACT TCCAGCCGGT GCTCCACCTG GTTGCCTCA ACAGCCCCCT G;	5 prime PCR primer for human endostatin
4	GCGCGCAAGC TTATTACTTG GAGGCAGTCA TGAAGCTGTT CTCAATGCAG AGCACCGATGT AGGCGTGATG GCAGCTCGC;	3 prime PCR primer for human endostatin
5		pMON42342 EcoR1 insert encoding mouse endostatin
6		pMON42343 EcoR1 insert encoding mouse endostatin
7		pMON42344 EcoR1 insert encoding mouse endostatin
8		pMON42345 EcoR1 insert encoding mouse endostatin
9		pMON20440 encoding human endostatin
10	AHTHQDFQPVLHLVALNTPLSGGMRGIRGADFQCFQQARA VGLSGTFRAFLSS RLQDLYSIVRRADRGCSVPIVNLKDEVLSPSWDSLFGSQG QLQPGARIFSFDFGRDV LRHPAWPQKSVWHGSDPSGRRLMESYCETWRTEATTGATGQ ASSLLSGRLLEQK AASCHNSYIVLCIENSFMTSFSK;	Mouse Endostatin Amino Acid Sequence
11	AHSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARA VGLAGTFRAFLSS RLQDLYSIVRRADRAAVPIVNLKDELLFPSWEALFSGSEG PLKPGARIFSFDFGKDV LRHPTWPQKSVWHGSDPNGRRLTESYCETWRTEAPSATGQ ASSLLGGRLLGQS AASCHHAYIVLCIENSFMTA-SK;	Human Endostatin Amino Acid Sequence

- 29 -

Claims

What is claimed is:

1. A method of producing endostatin comprising the steps of:
 - (a) culturing host cells that are expressing an endostatin gene;
 - 5 (b) recovering the product of said gene expression;
 - (c) solubilizing said gene product at an elevated pH;
 - (d) refolding said solubilized gene product at about a near-neutral pH; and
 - (e) isolating properly folded forms of said gene product.

10 2. A method of producing endostatin comprising the steps of:

- (a) culturing host cells that are expressing an endostatin gene;
- (b) recovering the product of said gene expression;
- (c) refolding said gene product at about a near neutral pH; and
- (d) isolating properly folded forms of said gene product.

15

3. The method of claim 1 wherein said elevated pH in the solubilizing step is from about pH 9 to about pH 11.5.

4. The method of claim 3 wherein said elevated pH is from about pH 10 to about pH 11.

20 5. The method of claim 4 wherein said elevated pH is about pH 10.5.

6. The method of claim 1 or claim 2 wherein said near-neutral pH in the refolding step is from about pH 6 to about pH 8.5.

- 30 -

7. The method of claim 6 wherein said near-neutral pH in the refolding step is from about pH 7.0 to about pH 8.0.
8. The method of claim 7 wherein said near-neutral pH in the refolding step is about pH 7.5.
- 5 9. The method of claim 6 wherein said near-neutral pH in the refolding step is from about pH 7.0 to about pH 8.0.
10. The method of claim 9 wherein said near-neutral pH in the refolding step is about pH 7.5.
- 10 11. The method of claim 1 or claim 2 wherein urea is present at a concentration of from about 4 M to about 10 M during said solubilization step.
12. The method of claim 11 wherein urea is present at a concentration of about 6 M during said solubilization step.
- 15 13. The method of claim 1 or claim 2 wherein urea is present at a concentration of from about 0.5 M to about 5 M during said refolding step.
14. The method of claim 13 wherein urea is present at a concentration of about 3.5 M during said refolding step.
- 20 15. The method of claim 1 or claim 2 wherein guanidine hydrochloride is present at a concentration of from about 2 M to about 8 M during said solubilization step.
16. The method of claim 15 wherein guanidine hydrochloride is present at a concentration of about 4 M during said solubilization step.
- 25 17. The method of claim 1 or claim 2 wherein guanidine hydrochloride is present at a concentration of from about 0.2 M to about 2 M during said refolding step.
18. The method of claim 17 wherein guanidine hydrochloride is present at a

- 31 -

concentration of about 1.5 M during said refolding step.

19. A method of claim 1 or 2 carried out in a presence of a reducing agent capable of reducing disulfide linkages to sulfhydryl groups.

5 20. A method of claim 19 wherein said reducing agent is selected from the group consisting of DTT, BME, cysteine, and reduced glutathione.

21. The method of claim 20 wherein DTT is present at a concentration of from about 2 mM to about 10 mM during said solubilization step.

10 22. The method of claim 21 wherein DTT is present at a concentration of about 5 mM during said solubilization step.

23. The method of claim 20 wherein DTT is present at a concentration of from about 0.2 mM to about 2 mM during said refolding step.

15 24. The method of claim 23 wherein DTT is present at a concentration of about 0.5 mM during said refolding step.

25. The method of claim 20 wherein reduced glutathione is present at a concentration of from about 5 mM to about 20 mM during said solubilization step.

20 26. The method of claim 25 wherein reduced glutathione is present at a concentration of about 10 mM during said solubilization step.

27. The method of claim 20 wherein reduced glutathione is present at a concentration of from about 1 mM to about 4 mM during said refolding step.

28. The method of claim 27 wherein reduced glutathione is present at a concentration of about 2 mM during said refolding step.

- 32 -

29. The method of claim 20 wherein cysteine is present at a concentration of from about 5 mM to about 20 mM during said solubilization step.
30. The method of claim 29 wherein cysteine is present at a concentration of about 10 mM during said solubilization step.
- 5 31. The method of claim 20 wherein cysteine is present at a concentration of from about 0.5 mM to about 4 mM during said refolding step.
32. The method of claim 31 wherein cysteine is present at a concentration of about 1 mM during said refolding step.
- 10 33. The method of claim 1 or claim 2 wherein an agent capable of enhancing the interchange of disulfide bonds is present during said refolding step.
34. The method of claim 33 wherein said agent is selected from cystine and oxidized glutathione.
- 15 35. The method of claim 34 wherein cystine is present at a concentration of from about 0.2 mM to about 5 mM during said refolding step.
36. The method of claim 35 wherein cystine is present at a concentration of about 1 mM during said refolding step.
37. The method of claim 1 or claim 2 wherein disulfide bonds are formed through air oxidation during said refolding step.
- 20 38. The method of claim 37 wherein said air oxidation step is carried out from about 12 hours to about 96 hours.
39. The method of claim 38 wherein said air oxidation step is carried out from about 24 hours to about 72 hours.
- 25 40. The method of claim 39 wherein said air oxidation step is carried out for about 60 hours.

- 33 -

41. The method of claim 1 or claim 2 wherein said gene product is present at a concentration of from about 1 to about 20 mg/ml during said solubilization step.

42. The method of claim 41 wherein said gene product is present at a concentration of about 2.5 mg/ml during said solubilization step.

5 43. The method of claim 1 or claim 2 wherein said gene product is present at a concentration of from about 0.1 to about 5 mg/ml during said refolding step.

44. The method of claim 43 wherein said gene product is present at a concentration of about 0.25 mg/ml during said refolding step.

10 45. The method of claim 1 or claim 2 which further includes the step of purifying the endostatin by a process selected from the group consisting of ion-exchange chromatography, hydrophobic interaction chromatography and RP-HPLC.


15 46. The method of claim 1 or claim 2 wherein said endostatin gene is comprised of DNA encoding non-human, animal endostatin.

47. The method of claim 1 or claim 2 wherein said endostatin gene is selected from the group consisting of SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8.

20 48. The method of claim 1 or claim 2 wherein said endostatin gene is comprised of DNA encoding human endostatin.

49. The method of claim 1 or claim 2 wherein said endostatin gene is comprised of SEQ ID NO: 9.

Figure 1



2 / 10

Figure 2

SOLUBILIZATION OF IBS IN
6 M UREA, 5 mM DTT (mouse) or 10 mM cysteine (human), pH 10.8
MIX 2 HOURS

⇓

ADDITION OF 10 mM CYSTINE,
MIX 5 MINUTES

⇓

DILUTE 10-FOLD TO
3.5 M Urea (Mouse) or 3.0 M Urea (Human) and
pH 7.0 (Mouse) or pH 7.5 (Human)
STIR 60 HOURS

3 / 10






Figure 3



4 / 10









Figure 4






5 / 10

Figure 5




6 / 10


Figure 6




7 / 10

Figure 7**Effect of Endostatin on HMEC Migration**

8 / 10


Figure 8**Effect of Endostatin on CPAE Migration**

9 / 10

Figure 9**Inhibition of Ba cEND Cell Proliferation by Mouse Endostatin**

10 / 10

Figure 10



Sequence Listing

SEQUENCE LISTING

```

<110> Harding, E.I.
      Violand, B.N.

<120> Method of producing mouse and human
      endostatin

<130> C_3071-0

<150> 60/075,587
<151> 1998-02-23

<160> 11

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 29
<212> DNA
<213> human

<400> 1
gcgcgcccat ggctcataact catcaggac                                29

<210> 2
<211> 38
<212> DNA
<213> human

<400> 2
gcgcgcaagc ttattatttg gagaaaaggagg tcatgaag                                38

<210> 3
<211> 71
<212> DNA
<213> human

<400> 3
gcgcgcccat ggctcacagc caccgcgact tccagccgt gtcacacctg gttgcgtca      60
acagccccct g                                71

<210> 4
<211> 79
<212> DNA
<213> human

<400> 4
gcgcgcaagc ttattacttg gaggcagtca tgaagctgtt ctcaatgcag agcacgtgt    60
aggcgtatg gcagctcg                                79

<210> 5
<211> 620
<212> DNA
<213> human

<400> 5
gcgcgcccat ggctcataact catcaggact ttcagccgt gtcacacctg gtggcactga    60
acaccccccgt gtcggaggc atgcgtggta tccgtggagc agattccag tgcttccagc    120
aagccccggc cgtggggctg tcggcacct tccgggctt cctgtccctt aggctgcagg    180
atctctatag catcgtgcgc cgtgctgacc gggggctgt gcccacatgc aacctgaagg    240
acgagggtgt atctcccaagc tgggactccc tggtttctgt ctcccaagggt caactgcaac    300
ccggggcccg catctttctt tttgacggca gagatgtctt gagacaccca gcctggccgc    360
agaagagcgt atggcacggc tcggacccca gtggggcggag gctgtatggag agttactgtg    420
agacatggcg aactgaaact actggggcta caggtcaggca ctccctccctg ctgtcaggca    480

```

ggctccctgga acagaaagct gcgagctgcc acaacagcta catcgccctg tgcattgaga atagctcat gaccctttc tcaagccgaa ttccagcaca ctggcgncgt tactagtat ccgagctcgta accaagttaa	540 600 620
<210> 6 <211> 582 <212> DNA <213> human	
<400> 6 gogccccat ggctcataact catcaggact ttcagccagt gctccacctg gtggcactga acaccccccgttccggaggt atgcgtggta tccgtggagc aaatttccag tgcttccagc aagccccggc cgtggggctg tcgggcacct tccgggctt cctgtccctt aggctgcagg atctctatay catcgccgc cgtgctgacc gggggctgtt gcccacatcgta aacctgaagg acgagggtgtt atctccggc tggactccc tggttctgg ctcccggtt caactgcaac ccggggcccg catctttctt ttgacggca gagatgtctt gagacaccca gcctggccgc agaagagcgt atggcacggc tcggacccca gtggcgagg gctgtatggag agttactgtg agacatggcg aactgaaact actggggcta caggtcaggc ctccctctg ctgtcaggca ggctccctgga acagaaagct gcgagctgcc acaacagcta catcgccctg tgcattgaga atagctcat gaccctttc tccaaataat aagcttggcg cg	60 120 180 240 300 360 420 480 540 582
<210> 7 <211> 580 <212> DNA <213> human	
<400> 7 gccccccatg ctctatactca tcaggacttt cagccagtgc tccacctgggt ggcactgaac accccccgtt ctggaggcat gcgtggatc cgtggaggcag atttccagtg ctccagcaa gccccggccg tggggctgtc gggcacccctt cgggctttcc tgcctcttag gctgcaggat ctctatacgac tcgtggcccg tgctgaccgg gggctgtc ccatgtcaa cctgaaggac gagggtgtat ctcccgatcg gggactccctt ttttctgggtt cccagggtca agtgcacacc ggggcccgca tctttttttt tgacggcaga gatgtctt gacacccagg ctggccgcag aagaggctat ggcaacggcgc ggaccccaagt gggcgaggc tgatggagag ttactgtgag acatggcgaa ctggaaactac tggggctaca ggtcaggctt cctccctgtt gtcaaggcagg ctccctggaaac agaaagctgc gagctgccac aacagctaca tgcgtccctgtt cattgagaat agcttcatga cctcttttcaaaataat gcttgcgcgc	60 120 180 240 300 360 420 480 540 580
<210> 8 <211> 568 <212> DNA <213> human	
<400> 8 catgctcata ctcatcgaga ctttcagcca gtgctccacc tggtggcact gaacacccccc ctgtctggag gcatgcgtgg tatccgtggta gcagattttc agtgccttcca gcaagcccgaa gcccggggc tgctgggtcac cttccgggtt ttccctgtt ctaggtgtca ggatctctat agcatgtgc gccgtgtga cccgggggtt gtgcccacatcg tcaacactgaa ggacggagggt ctatctccca gctggggactc cctgttttgc tgatggcacc gtcggatgtca acccgccggcc cgcatctttt cttttgacggcagagatgtc ctgagacacc cagcctggcc cagaagagc gtatggcacc gctcggacc cagtgccggcagg ggtgtatgg agagttactg tgagacatgg cgaactgaaa ctactggggc tacagatgtc gcctccccc tgctgtcagg caggtcctg gaacagaaaatgctggcgatcg ccacaacacc tacatgtcc tgcatttga gaatagctt atgacccttttctccaaataataat gcttgcgcgc	60 120 180 240 300 360 420 480 540 568
<210> 9 <211> 563 <212> DNA <213> human	
<400> 9 catggcacag ccacccgcac ttccagccgg tgctccaccc ggttgcgcctc aacagccccc tgtcaggccgg catgcggggc atccgcgggg ccgacttcca gtgctccag caggcgccgg ccgtggggctt ggcggggcacc ttccgcgcctt ccctgtccctc gcccgcgc gacctgtaca gcacatgtgc cccgtccgc cccgcgcgc tgccatgtt caacactaag gacggactgt tggtttccatcg ctggggaggctt ctgttctcgat gctctgtatgg tccgtgtt gacccggggc gcacatcttc ctttgacggc aaggacgtcc tgaggccacc caccctggcc cagaagagc tgtggcatgg ctccggaccacc aacggggcgc ggtgtaccga gagctactgt gacgtggc ggacggaggc ttccctggcc acggggccagg cccctcgat gctggggggc aggttccctgg	60 120 180 240 300 360 420 480

- 3 -

ggcagagtgc	cgcgagctgc	catcacgcct	acatcggtgct	ctgcatttag	aacagcttca	540									
tgactgcctc	caagtaataa	gct				563									
<210>	10														
<211>	124														
<212>	PRT														
<213>	human														
<400>	10														
Ala	His	Thr	His	Asp	Val	His	Val	Ala	Asn	Thr	Ser	Gly	Gly	Met	Arg
1					5					10				15	
Gly	Arg	Gly	Ala	Asp	Cys	Ala	Arg	Ala	Val	Gly	Ser	Gly	Thr	Arg	Ala
						20				25				30	
Ser	Ser	Arg	Asp	Tyr	Ser	Val	Arg	Arg	Ala	Asp	Arg	Gly	Ser	Val	Val
						35				40				45	
Asn	Lys	Asp	Val	Ser	Ser	Trp	Asp	Ser	Ser	Gly	Ser	Gly	Gly	Ala	Arg
							50			55				60	
Ser	Asp	Gly	Arg	Asp	Val	Arg	His	Ala	Trp	Lys	Ser	Val	Trp	His	Gly
							65			70				80	
Ser	Asp	Ser	Gly	Arg	Arg	Met	Ser	Tyr	Cys	Thr	Trp	Arg	Thr	Thr	Thr
							85			90				95	
Gly	Ala	Thr	Gly	Ala	Ser	Ser	Ser	Gly	Arg	Lys	Ala	Ala	Ser	Cys	His
							100			105				110	
Asn	Ser	Tyr	Val	Cys	Asn	Ser	Met	Thr	Ser	Ser	Lys				
							115			120					
<210>	11														
<211>	123														
<212>	PRT														
<213>	human														
<400>	11														
Ala	His	Ser	His	Arg	Asp	Val	His	Val	Ala	Asn	Ser	Ser	Gly	Gly	Met
1						5				10				15	
Arg	Gly	Arg	Gly	Ala	Asp	Cys	Ala	Arg	Ala	Val	Gly	Ala	Gly	Thr	Arg
							20			25				30	
Ala	Ser	Ser	Arg	Asp	Tyr	Ser	Val	Arg	Arg	Ala	Asp	Arg	Ala	Ala	Val
							35			40				45	
Val	Asn	Lys	Asp	Ser	Trp	Ala	Ser	Gly	Ser	Gly	Lys	Gly	Ala	Arg	Ser
							50			55				60	
Asp	Gly	Lys	Asp	Val	Arg	His	Thr	Trp	Lys	Ser	Val	Trp	His	Gly	Ser
							65			70				80	
Asp	Asn	Gly	Arg	Arg	Thr	Ser	Tyr	Cys	Thr	Trp	Arg	Thr	Ala	Ser	Ala
							85			90				95	
Thr	Gly	Ala	Ser	Ser	Gly	Arg	Gly	Ser	Ala	Ala	Ser	Cys	His	His	
							100			105				110	
Ala	Tyr	Val	Cys	Asn	Ser	Met	Thr	Ala	Ser	Lys					
							115			120					

INTERNATIONAL SEARCH REPORT

Inte .onal Application No
PCT/US 99/03271

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/78 C12P21/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'REILLY M S ET AL: "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth" CELL, vol. 88, no. 88, 24 January 1997 (1997-01-24), pages 277-285 285, XP002099773 ISSN: 0092-8674 cited in the application the whole document ---	1,2, 6-13,27, 28,33, 34, 41-44, 46-49
X	WO 97 15666 A (CHILDRENS MEDICAL CENTER) 1 May 1997 (1997-05-01) cited in the application abstract page 38, line 16 - page 40, line 23 claim 5 ---	1,2, 6-12,46, 47 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

20 July 1999

03/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

INTERNATIONAL SEARCH REPORT

Inte. .onal Application No

PCT/US 99/03271

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	DHANABAL ET AL: "Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma" CANCER RESEARCH, vol. 59, no. 1, 1 January 1999 (1999-01-01), pages 189-197, XP002100110 ISSN: 0008-5472 the whole document ---	1, 2, 6-12, 46, 47
A	STÄNDKER L. ET AL.: "Isolation and characterization of the circulating form of human endostatin" FEBS LETT., vol. 420, 1997, pages 129-133, XP002109286 cited in the application the whole document ---	1-49
A	HERMANN R: "STANDARD TECHNIQUES FOR PROTEIN SOLUBILISATION AND UNFOLDING" 1993 , PROTEIN FOLDING XP002056863 page 1 - page 6 page 13 - page 16 page 50 - page 53 page 89 - page 92 page 107 - page 111 ---	1-49
A	EP 0 219 874 A (BOEHRINGER MANNHEIM GMBH) 29 April 1987 (1987-04-29) the whole document & EP 0 393 725 A (BOEHRINGER MANNHEIM) 24 October 1990 (1990-10-24) ---	1-49
A	WO 96 40736 A (CELTRIX PHARMA) 19 December 1996 (1996-12-19) abstract page 5, line 24 - page 7, line 25 page 13, line 16 - page 14, line 30 examples 1-5 ---	1-49
A	WO 97 18233 A (PHARMACIA & UPJOHN AB ;GUSTAFSSON JAN GUNNAR (SE); OEHMAN JOHAN (S) 22 May 1997 (1997-05-22) abstract examples 1-3 ---	1-49
A	EP 0 312 358 A (PITMAN MOORE INC) 19 April 1989 (1989-04-19) abstract -----	1-49

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No

PCT/US 99/03271

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9715666	A	01-05-1997		US 5854205 A AU 7466696 A CN 1202932 A CZ 9801177 A EP 0857210 A NO 981803 A NZ 321356 A		29-12-1998 15-05-1997 23-12-1998 12-08-1998 12-08-1998 17-06-1998 25-11-1998
EP 0219874	A	29-04-1987		DE 3537708 A AT 98648 T AT 131489 T AU 607083 B AU 4132189 A AU 590029 B AU 6599386 A CA 1329157 A CZ 8607526 A DE 3650449 D DE 3689404 D DK 320387 A WO 8702673 A EP 0253823 A EP 0393725 A ES 2061434 T ES 2020498 T FI 872753 A, B, FI 933868 A, B, GR 92300062 T GR 3018410 T HK 153496 A HK 153596 A HR 921075 A IE 62634 B JP 2117325 C JP 4218387 A JP 8024594 B JP 7028745 B JP 62502895 T LV 5289 A PT 83609 A, B SI 8611796 A, B SK 752686 A US 5453363 A US 5593865 A YU 179686 A		23-04-1987 15-01-1994 15-12-1995 21-02-1991 04-01-1990 26-10-1989 19-05-1987 03-05-1994 17-01-1996 25-01-1996 27-01-1994 23-06-1987 07-05-1987 27-01-1988 24-10-1990 16-12-1994 01-04-1996 22-06-1987 03-09-1993 31-08-1992 31-03-1996 16-08-1996 16-08-1996 30-06-1995 22-02-1995 06-12-1996 07-08-1992 13-03-1996 05-04-1995 19-11-1987 10-10-1993 01-11-1986 31-10-1996 01-10-1996 26-09-1995 14-01-1997 30-06-1988
WO 9640736	A	19-12-1996		US 5789547 A AU 703489 B AU 5957696 A CA 2223495 A CN 1214689 A CZ 9703943 A EP 0832098 A NO 975749 A PL 323731 A		04-08-1998 25-03-1999 30-12-1996 19-12-1996 21-04-1999 16-09-1998 01-04-1998 27-01-1998 14-04-1998
WO 9718233	A	22-05-1997		AU 705192 B AU 7659696 A		20-05-1999 05-06-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/03271

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9718233	A	CA NO	2236751 A 982155 A	22-05-1997 12-05-1998
EP 0312358	A	19-04-1989	AU CN JP	2370288 A 1033073 A, B 1132598 A